VIDEO: ASCO 2014 roundtable on breast cancer research

CHICAGO – The Oncology Report associate editors Dr. William J. Gradishar and Dr. Hope S. Rugo discuss breast cancer research highlights presented at the 2014 annual meeting of the American Association of Clinical Oncology.

Studies discussed include the combined analysis of the SOFT and TEXT trials, looking at ovarian suppression in combination with either an aromatase inhibitor or tamoxifen; ALTTO, looking at the impact of a dual blockade against HER2, and the implications on the use of pCR in research and drug approval; ECOG 5103 adjuvant bevacizumab trial; and POEMS, looking at the possibility of preserving fertility during chemotherapy with the addition of goserelin. 

Dr. William J. Gradishar is the Betsy Bramsen Professor of Breast Oncology at the Northwestern University, Chicago. Dr. Hope S. Rugo is a professor of medicine, University of California, San Francisco, and director, breast oncology and clinical trials education, UCSF Helen Diller Family Comprehensive Cancer Center.

CHICAGO – The Oncology Report associate editors Dr. William J. Gradishar and Dr. Hope S. Rugo discuss breast cancer research highlights presented at the 2014 annual meeting of the American Association of Clinical Oncology.

Studies discussed include the combined analysis of the SOFT and TEXT trials, looking at ovarian suppression in combination with either an aromatase inhibitor or tamoxifen; ALTTO, looking at the impact of a dual blockade against HER2, and the implications on the use of pCR in research and drug approval; ECOG 5103 adjuvant bevacizumab trial; and POEMS, looking at the possibility of preserving fertility during chemotherapy with the addition of goserelin. 

Dr. William J. Gradishar is the Betsy Bramsen Professor of Breast Oncology at the Northwestern University, Chicago. Dr. Hope S. Rugo is a professor of medicine, University of California, San Francisco, and director, breast oncology and clinical trials education, UCSF Helen Diller Family Comprehensive Cancer Center.

CHICAGO – The Oncology Report associate editors Dr. William J. Gradishar and Dr. Hope S. Rugo discuss breast cancer research highlights presented at the 2014 annual meeting of the American Association of Clinical Oncology.

Studies discussed include the combined analysis of the SOFT and TEXT trials, looking at ovarian suppression in combination with either an aromatase inhibitor or tamoxifen; ALTTO, looking at the impact of a dual blockade against HER2, and the implications on the use of pCR in research and drug approval; ECOG 5103 adjuvant bevacizumab trial; and POEMS, looking at the possibility of preserving fertility during chemotherapy with the addition of goserelin. 

Dr. William J. Gradishar is the Betsy Bramsen Professor of Breast Oncology at the Northwestern University, Chicago. Dr. Hope S. Rugo is a professor of medicine, University of California, San Francisco, and director, breast oncology and clinical trials education, UCSF Helen Diller Family Comprehensive Cancer Center.